Drug approvals are no longer permanent guarantees of market tenure.
The regulatory victory of securing a drug approval is increasingly fragile, as agencies aggressively weaponize post-marketing confirmatory trials and safety reviews to claw back market access.
The same conclusion keeps arriving from across the workspace's research — 1 topics independently instantiate this theme. Filter the evidence by where it came from:
An approved drug's market tenure is actively threatened as the FDA attempts to revoke its green light after discovering clinical trial errors.
It showcases how unexpected safety signals emerging during a mandatory, post-market confirmatory trial can jeopardize the permanent approval path for accelerated drugs.
European authorities recommended withdrawing Tavneos's approval because underlying trial data breaches compromised its established safety and efficacy profiles.
Discovery of trial irregularities and data manipulation has led both U.S. and European regulators to initiate processes to revoke Tavneos's approved status.
A second consecutive clinical failure in post-marketing confirmatory trials has placed Zepzelca's accelerated FDA approval under imminent threat of revocation.
Zepzelca's initial accelerated approval is in jeopardy due to a second failed confirmatory trial in the target patient popuation.